Oral presentation will highlight final data from Phase 2 M-PLACE study of felzartamab in patients with Primary Membranous Nephropathy SOUTH SAN FRANCISCO, Calif., Oct. 13, 2023 /PRNewswire/ — Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing…
